Background: Caspase activation and recruitment domain 11 (CARD11) encodes a scaffold protein in lymphocytes that links antigen receptor engagement with downstream signaling to nuclear factor kB, c-Jun N-terminal kinase, and mechanistic target of rapamycin complex 1. Germline CARD11 mutations cause several distinct primary immune disorders in human subjects, including severe combined immune deficiency (biallelic null mutations), B-cell expansion with nuclear factor kB and Tcell anergy (heterozygous, gain-of-function mutations), and severe atopic disease (loss-of-function, heterozygous, dominant interfering mutations), which has focused attention on CARD11 mutations discovered by using whole-exome sequencing. Objectives: We sought to determine the molecular actions of an extended allelic series of CARD11 and to characterize the expanding range of clinical phenotypes associated with heterozygous CARD11 loss-of-function alleles. Methods: Cell transfections and primary T-cell assays were used to evaluate signaling and function of CARD11 variants. Results: Here we report on an expanded cohort of patients harboring novel heterozygous CARD11 mutations that extend beyond atopy to include other immunologic phenotypes not previously associated with CARD11 mutations. In addition to (and sometimes excluding) severe atopy, heterozygous missense and indel mutations in CARD11 presented with immunologic phenotypes similar to those observed in signal transducer and activator of transcription 3 loss of function, dedicator of cytokinesis 8 deficiency, common variable immunodeficiency, neutropenia, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome. Pathogenic variants exhibited dominant negative activity and were largely confined to the CARD or coiled-coil domains of the CARD11 protein.
Conclusion: These results illuminate a broader phenotypic spectrum associated with CARD11 mutations in human subjects and underscore the need for functional studies to demonstrate that rare gene variants encountered in expected and unexpected phenotypes must nonetheless be validated for pathogenic activity. (J Allergy Clin Immunol 2019;143:1482-95.)
Key words: CARD11, atopy, atopic dermatitis, dominant negative, primary immunodeficiency, immune dysregulation Hypomorphic mutations in genes with protein products that are critical for immune function provide an opportunity to assess the protein's roles in the context of a functioning but impaired immune response. Unlike the unresponsive or absent effector compartments often associated with null mutations that manifest as severe combined immune deficiency, these mutations preserve sufficient function to allow for development of the particular cells or organs with which it is involved. Studies of such allelic variants in mice and other model organisms have taught us much about immune system development and function. With the wider availability and application of next-generation sequencing technologies, we now have more opportunities to explore the phenomenon of allelic variance and phenotypic heterogeneity in human subjects. One example can be found in the case of recombination-activating gene 1 (RAG1): null mutants lead to the absence of T cells and grossly abnormal thymic development. Hypomorphic mutations lead to functioning T cells but disruptions of repertoire and thymic development that shed light on immune tolerance, RAG1 protein domain function, and other immune processes. 1 Another example is found in different types of mutations described in caspase activation and recruitment domain 11 (CARD11), leading to different phenotypes. CARD11 is a critical 1154-amino-acid protein scaffold best known for linking antigen recognition with downstream nuclear factor kB (NF-kB) activation in lymphocytes. 2, 3 The protein CARD11 (also known as CARMA1 and represented by the sequences NP_115791.3 and NM_032415) includes an N-terminal caspase recruitment domain (CARD; 1-110), LATCH (112-130), coiled-coil (CC, 130-449) domains, and a C-terminal membrane-associated guanylate kinase domain (667-1140) comprised of the PDZ, SH3, and GUK domains. Biallelic null mutations of CARD11 in both patients and mouse models lead to severe T-and B-cell immune deficiency. 4 Somatic gain-of-function (GOF) CARD11 mutations are commonly found in patients with non-Hodgkin B-cell lymphomas, whereas germline GOF mutations give rise to B-cell expansion with nuclear factor kB and T-cell anergy (BENTA) disease in human subjects. 2, 5, 6 Surprisingly, hypomorphic/dominant negative (DN) mutations in both mice and human subjects permit sufficient effector function to reveal a strong disposition toward atopic phenotypes in addition to variable immune deficiency. [7] [8] [9] Because CARD11 oligomerization is essential for downstream signaling, heterozygous variants can either enhance or dominantly interfere with CARD11 function. 10, 11 Greater access to next-generation sequencing virtually guarantees that variants in a particular gene can now be identified in patients with ever-broadening phenotypes, especially for cases of GOF and hypomorphic loss-of-function (LOF) mutations. 12 Although algorithms can assist in predicting which variants are likely to be benign or deleterious, previously undescribed rare or novel variants in such genes must always be validated for pathogenicity by using relevant biological assays. Moreover, in silico prediction methods do not distinguish between variants seen in the heterozygous and homozygous states, which is critical for CARD11. Furthermore, collection and testing of variants from as many centers as possible can more accurately determine the breadth of disease associated with a given gene, especially given the role that referral bias can play in any given center. Therefore we report our experience with numerous heterozygous mutations in CARD11 in the context of severe familial atopic disease and other immunologic phenotypes not previously associated with CARD11 mutations. The atopy described here is a genetic tendency to develop symptoms of immediate hypersensitivity (eg, food allergy and allergic rhinitis) or allergic inflammation (eg, eczema and eosinophilic esophagitis), irrespective of specific allergen sensitization. 13 In many cases rare or novel mutations were uncovered in whole-exome sequencing (WES)/wholegenome sequencing performed at major referral centers for multiple reasons, particularly in patients without a clear putative genetic diagnosis.
Here we attribute several new DN CARD11 mutations to an expanded list of disease manifestations and describe assays designed to help differentiate pathogenic versus nonpathogenic variants in CARD11. Importantly, results of these assays are interpreted within the context of specific genotypic/phenotypic criteria that help to define a differential diagnosis for patients harboring CARD11 DN mutations. In addition to severe atopy, heterozygous missense mutations in CARD11 with DN activity can present with common variable immunodeficiency (CVID), neutropenia, cutaneous viral infections, and immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)-like syndrome. Collectively, our findings define a broader spectrum of immune disease associated with detrimental CARD11 mutations, which are most often confined to specific domains of the CARD11 protein. Nevertheless, our evaluations underscore the idea that rare gene variants found by using WES/whole-genome sequencing can be pathogenic even when not matching with reported phenotypes. At the same time, CARD11 mutations associated with an expected phenotype must nonetheless be validated for pathogenic activity by using functional studies.
METHODS Patients
Informed consent was obtained from all participating patients and their family members according to protocols approved by institutional review and ethics boards at their respective institutions.
WES and genetic analysis
WES was performed in the majority of patients described here, according to established protocols. For example, kindreds 6, 19, and 29 were analyzed as follows. Genomic DNA was extracted from peripheral blood cells, and the Illumina paired-end genomic DNA sample preparation kit (PE-102-1001; Illumina, San Diego, Calif) was used for preparing the libraries, followed by the exome-enriched library with the Illumina TruSeq exome kit (FC-121-1008; Illumina). Samples were sequenced on an Illumina HiSeq as 100-bp paired-end reads. DNA reads were mapped to the GRCh38 human genome reference by using the default parameters of the Burrows-Wheeler Aligner (bio-bwa.sourceforge.net). Single nucleotide substitutions and small insertion deletions were identified and filtered based on quality with SAMtools software package (samtools.sourceforge.net) and annotated with the Annovar tool (www.openbioinformatics.org). Filtering of variants for novelty was performed according to minor allele frequency, mouse mutant phenotype in the homologous mouse gene, Mendelian disease associations (OMIM), pathway analysis (gene ontology), immune system expression (Immgen), CADD, SIFT, and PolyPhen-2 scores. [14] [15] [16] After filtering and ranking variants, heterozygous CARD11 variants were investigated further. Kindred 14 (R187P) was initially evaluated separately from the other families. Eight samples were subjected to WES, as described previously (see the Methods section in this article's Online Repository at www.jacionline. org). 17 We selected putative causative variants that had an average read depth of 20 or greater and a quality score of 200 or greater and were heterozygous in at least 1 subject. Genetic analysis showed that 7 of the samples were related and 1 sample was not related. The remaining 7 samples were from 1 unaffected subject and 6 affected subjects. We did a combinatorial search for variants present in the heterozygous state in the 6 affected subjects and absent in the unaffected subject. We performed multipoint genetic linkage analysis with Superlink Online SNP, 18, 19 assuming a rare disease allele and dominant inheritance. Two variants satisfied the combinatorial condition of being heterozygous in 6 sampled affected subjects and absent in the 1 sampled unaffected subject, MICALL2 (p.Q202*) and CARD11 (p.R187P), and were at the same time located in a region (chromosome 7: 0.0-4.3 Mbp) consistent with genetic linkage.
PBMC signaling analysis
PBMCs were isolated by using Ficoll gradient centrifugation. Phosphorylation of p65 and/or S6 and degradation of IkB were assessed by using intracellular flow cytometry after short ex vivo stimulations with phorbol 12-myristate 13-acetate, as previously described. 9 Total PBMCs (10 6 /mL) were seeded in 1 mL of RPMI (Gibco, Carlsbad, Calif) supplemented with 10% FBS, penicillin/streptomycin, and L-glutamine in an anti-CD3 antibody (OKT3, 1 mg/mL)-coated 48-well plate to assess S6 phosphorylation under T H 0 conditions. Anti-CD28 antibody (L293, 0.2 mg/mL) and IL-2 (10 ng/mL; PeproTech, Rocky Hills, NJ) were then added to the culture (T H 0), and cells were incubated in a 378C CO 2 chamber. After 24 hours, cells were pelleted by means of centrifugation, stained with Live/Dead dye (Thermo Fisher, Waltham, Mass), fixed with 1.6% paraformaldehyde in PBS, and then centrifuged and permeabilized with absolute methanol.
Cells were then stained for flow cytometry with fluorochrome-conjugated antibodies after washes with FACS buffer (PBS with 0.5% BSA). The antibodies used for flow cytometry were as follows: CD3 (UCHT1), CD4 (RPA-T4, L200), CD45RA (HI100), and phospho-S6 (N7-548; BD Biosciences, San Jose, Calif). Percentages of phospho-S6
1 live CD3 1 CD4 1 cells gated on the lymphocyte side-scatter and CD45RA compartments are shown.
CARD11 mutant expression plasmids
Modified wild-type (WT) and mutant pUNO-CARD11-FLAG plasmids were constructed and purified, as previously described. 9 Briefly, site-directed mutagenesis was used to introduce single nucleotide variants that were putative point mutations into the WT CARD11 construct (InvivoGen, San Diego, Calif) by using primer-directed linear amplification with Pwo or PfuI polymerase (Roche, Mannheim, Germany), followed by DpnI digestion of methylated template DNA (Thermo Fisher). All inserted variants were confirmed by using Sanger sequencing. All resulting plasmids were purified from DH5a Escherichia coli (New England Biolabs, Ipswich, Mass) with a GenElute HP Plasmid Maxi-Prep Kit (Sigma, St Louis, Mo).
Cell transfection assays
Both WT (clone E6.1, ATCC) and CARD11-deficient Jurkat T cells (referred to as JPM50.6 cells) were cultured and transfected as previously described.
9 JPM50.6 cells containing an integrated canonical NF-kB-driven green fluorescent protein (GFP) reporter were originally provided by Dr Xin Lin (MD Anderson Cancer Center, Houston, Tex). Briefly, 5 3 10 6 Jurkat or JPM50.6 T cells were resuspended in 0.4 mL of RPMI/10% FBS, placed in 0.4-cm cuvettes (Bio-Rad Laboratories, Hercules, Calif), and electroporated (260 V, 950 mF) with 5 to 10 mg of plasmid DNA (BTX; Harvard Apparatus, Holliston, Mass). JPM50.6 cells were stimulated 24 hours after transfection with 1 mg/mL anti-CD3/CD28 antibodies and incubated overnight (BD Biosciences). Relative canonical NF-kB activation in JPM50.6 cells was quantified based on mean fluorescence intensity (MFI) of an integrated kB-GFP reporter with an Accuri C6 flow cytometer (BD Biosciences).
Cells were washed 24 hours after transfection in PBS and incubated in PBS/ 1%BSA for 1 hour at 378C to assess S6 phosphorylation in Jurkat transfectants. After an additional PBS wash, cells were stimulated with 1 mg/mL anti-CD3/CD28 antibodies (BD Biosciences) for 20 minutes at 378C. Activation was stopped by adding ice-cold PBS, and cells were pelleted and lysed in 1% NP-40 lysis buffer, as previously described. 9 Lysates (5-10 mg) were separated on 4-20% Tris-Glycine SDS gels and transferred to nitrocellulose membranes (Bio-Rad Laboratories). Membranes were blocked in 5% milk/TBS/0.1% Tween 20 and immunoblotted with the following antibodies: anti-phospho-S6 (Ser235/236), anti-S6 (5G10), anti-CARD11 (1D12, Cell Signaling Technology, Danvers, Mass; LS-C368868, LifeSpan Biosciences, Seattle, Wash; and OASG00985, Aviva Systems Biology, San Diego, Calif), anti-HA (2-2.2.14, Thermo Fisher), anti-FLAG (M2), and anti-b-actin (AC-15, Sigma). Blots were washed 3 times in TBS/ 0.1% Tween 20, incubated in horseradish peroxidase-conjugated secondary antibodies (SouthernBiotech, Birmingham, Ala), and washed again. Bands were visualized by means of enhanced chemiluminescence (Thermo Fisher) and imaged on a ChemiDoc system (Bio-Rad Laboratories). Spot densitometric quantification of phospho-S6 versus total S6 was performed with ImageLab software (Bio-Rad Laboratories).
Hierarchical clustering analysis
Hierarchical clustering with a complete linkage algorithm and an asymmetric binary distance measure (for binary variables) was used to explore the data contained in Table E1 in this article's Online Repository at www.jacionline.org. Primarily because of a significant proportion of missing data across many of the variables, only a subset of variables was included in the clustering algorithm. Moreover, only subjects with complete data on the chosen subset were included in the hierarchical clustering. Models were also run using different variable sets, distance measures, and clustering algorithms, and this led to different sets of clusters. Hence presented results should be considered exploratory and descriptive.
Unsupervised patient clustering
To depict patients with their phenotypic attributes in 2-dimensional space, we used Gower distance transformation (as implemented in the daisy function in the R cluster v2.0.7-1 package), [20] [21] [22] which handles data sets with missing data points, followed by t-distributed stochastic neighbor embedding (tSNE), 23 as implemented in the Rtsne v0.13 library (by using the settings theta 5 0 and perplexity 5 10). Next, we divided the patient cohort into 3 clusters by using K-means clustering in R (K 5 3). The process of using tSNE and K-means to cluster patients was repeated over 10 trials, and consensus assignment was used to assign each patient to a final cluster ID.
To identify phenotypes important for each cluster, we performed attribute selection and logistic regression in Weka v3.8.2. 24 For attribute selection, we used the Fast Correlation-based Feature Search method 25 to select nonredundant attributes. Using the selected attributes, we performed multinomial logistic regression using the SimpleLogistic function 26 with 5-fold cross-validation to build a classifier for assigning patients to one of the 3 clusters. The features selected along with their predicted coefficients allowed us to assess the importance of phenotypes for each class separately. Based on 10 randomized trials, the classifier demonstrated an overall accuracy of 88.1% with an SD of 611.7%. Sensitivity and specificity for the trials were 98.33% 6 8.42% and 93.90% 6 11.03%, respectively.
Statistics
For JPM50.6 cell transfections, 2-way ANOVAs with Sidak correction were used to compare GFP MFI between WT and mutant CARD11. Phospho-S6/total S6 protein densitometric ratios were normalized to WT values and compared by using a Wilcoxon signed-rank test. For primary cell assays, experimental and technical replicates were limited by the small numbers of patient samples available. For patients in kindreds 6, 19, and 29, ratios of phospho-S6 geometric MFI (stimulated/unstimulated) were compared with those in healthy control subjects (matched per experiment) by using a KruskalWallis test.
RESULTS
Novel DN CARD11 mutations detected in a broad spectrum of immune disorders Rare or novel CARD11 mutations were identified by allergy and primary immunodeficiency referral centers in patients with immune-deficient or dysregulatory phenotypes (Table I) . A total of 48 new patients in 27 families with 26 different heterozygous germline CARD11 variants were referred. Salient patient phenotypes, combined with those already reported, 7, 9 are summarized in Tables I and II . These alleles were then evaluated at centers specializing in CARD11 biology and associated diseases and pathways.
First, we investigated whether each variant altered T-cell receptor (TCR) signaling. Each CARD11 variant was cloned into an expression construct and transfected into WT Jurkat or CARD11-deficient Jurkat (JPM50.6) T-cell lines. As a control, we also tested a variant (p.C150L) identified as a somatic reversion mutant that restored NF-kB signaling in T cells from a CARD11-deficient patient with Omenn syndrome. 27 Upon CD3/CD28 stimulation of transfected JPM50.6 cells, 14 of 26 mutants demonstrated significantly reduced NF-kB activation, indicating LOF (Fig 1, A) . Two variants (p.P495S and p.R848C) displayed enhanced NF-kB activation only after stimulation; unlike BENTA-associated mutations, these variants did not induce constitutive NF-kB activity.
Because all variants were heterozygous, we next tested whether each LOF mutants could dominantly interfere with WT CARD11 signaling when coexpressed at 50:50 ratios. Among 14 LOF mutations, DN activity (defined as significantly reduced NF-kB activation relative to 100% WT expression) was observed for 10 (Fig 1, B) . Most of these new DN variants were confined to the CARD domain and proximal CC domains, which are critical for both CARD11 oligomerization and BCL10-MALT1 interactions. 28, 29 All variants were comparably expressed in transfected cells, suggesting none of the mutations tested affected CARD11 protein translation and stability (Fig 1, C , and data not shown). Although a faint 15-kDa band was noted on prolonged blot exposure, we could not definitively confirm the presence of a truncated K143X protein by means of immunoblotting with available N-terminus specific CARD11 antibodies, which cross-reacted with many nonspecific proteins (data not shown). However, the fact that expression of this construct and not the Q945X truncation mutant 9 exhibits DN activity strongly suggests that it is expressed. Moreover, a K143X CARD11 expression construct engineered to include a C-terminal HA-tag was clearly expressed in JPM50.6 transfectants and exhibited comparable DN activity compared with the untagged form (see Fig E1 in this article's Online Repository at www.jacionline.org).
CARD11 also affects TCR-induced mechanistic target of rapamycin complex 1 (mTORC1) activation. 30 ,31 Therefore we further tested whether selected CARD11 variants could disrupt TCR-induced mTORC1 activation by measuring ribosomal S6 protein phosphorylation using immunoblotting. For most mutations within the CARD domain, we observed a trend toward decreased phospho-S6 levels (Fig 1, C and D) , similar to those seen in previously characterized DN mutants. 9 However, these differences did not reach statistical significance because of the inherent variation in our assays. mTORC1 signaling is exquisitely sensitive to subtle perturbations in cell viability, culture media contents, and stimulation conditions, particularly in Jurkat T cells (K. Hamilton, personal communication). Interestingly, some mutants (eg, p.R72G and p.R187P) had no appreciable effect on TCR-induced S6 phosphorylation despite impaired NF-kB activation in Jurkat transfectants (Fig 1, C and D) . Collectively, these transfection results suggest that bona fide DN mutations in CARD11, which are often located in the CARD domain, attenuate TCR-induced NF-kB activation with variable effects on mTORC1 signaling (Fig 1, E) .
Patient phenotypes with DN CARD11 mutations
We compared a total of 60 patients from 32 kindreds carrying heterozygous CARD11 variants (Table I) . Including those previously published, 7, 9 we identified 28 distinct CARD11 alleles, of which 14 are DN, as determined by using the functional assays described above. All kindred pedigrees with confirmed CARD11 DN variants are shown in Fig 2. All patients were referred with immunologic phenotypes for investigation, typically presenting in childhood. Therefore we compared manifestations in those with functional CARD11 DN defects with those in patients with no obvious DN functional defect, even if hypomorphic (Tables I and II) . Severe atopic dermatitis (AD) was present in most patients with DN mutations (32/44 [73%]), compared with non-DN variants (5/16 [31%]). Other atopic symptoms were noted in patients with DN variants, including asthma (55%) and food allergies (32%) and, less frequently, rhinitis and eosinophilic esophagitis (Table I) . Cutaneous viral infections were also more common in patients with DN alleles, including molluscum contagiosum (52%), cutaneous herpes simplex virus 1 infection (30%), and warts (27%; Table I ). We also observed cases of neutropenia and presentations similar to other syndromes associated with increased IgE levels and infections (kindred 14), including IPEX-like syndrome (kindred 4), in patients with functional DN alleles but not in others. Of note, the patient with an IPEX-like presentation (including failure to thrive, bloody diarrhea, and severe eczema) carried the identical mutation (p.R30W) as described recently by Dadi et al 7 (kindred 5) in a family with severe atopy, infection, and mild (late-onset) autoimmunity. Prominent phenotypes in the collective cohort of patients with CARD11 DN mutations are summarized in Table II . In addition to atopic disease (89%), significant viral skin infections (68%) and lung diseases (eg, infections, pneumonia, and bronchiectasis; 68%) were the most prominent symptoms shared by patients harboring DN CARD11 mutations (Table II) . Additional phenotypes included autoimmunity (20%), most commonly alopecia but also including idiopathic thrombocytopenic purpura and bullous pemphigoid. Neutropenia was also observed in 5 (14%) patients (including 4 with no demonstrable atopic disease), although an autoimmune cause could not be confirmed. Oral ulcers were also observed (14%) and might be linked to neutropenia. Four patients had lymphoproliferative disease (large granular lymphocytic leukemia, peripheral T-cell lymphoma, and/or mycosis fungoides). Notably, 3 patients from 2 families had little to no atopic disease (1 had a mild IgE levels increase without clinical manifestations) but did have neutropenia with humoral defects including progressive B-cell lymphopenia, poor class-switched B-cell memory, and antibody deficiency. Indeed, low IgM levels and impaired humoral responses to certain vaccines (eg, pneumococcal) were observed in several patients. Relevant immunologic phenotypes, including total and specific antibody defects and lymphocyte subsets, are summarized in Table III and  Table E1 in this article's Online Repository at www. jacionline.org. Hierarchical clustering with a complete linkage algorithm and an asymmetric binary distance measure was used to explore the cohort for specific phenotypic patterns for patients (n 5 36) and phenotypes (n 5 7) for which phenotypic data were more complete. Although the small size of the cohort precludes any assessment of statistical significance, descriptively we saw (1) a cluster of neutropenic patients with low IgM and lower IgE levels, (2) patients with AD and asthma who had low IgM levels, (3) patients with AD without asthma who had low IgG and low IgA levels, and (4) patients with high IgA levels, normal IgM levels, lack of neutropenia, and IgE levels that tracked with the presence of AD (see Fig E2, A, in this article's Online Repository at www. jacionline.org). These clusters did not appear to correlate with specific mutations.
To be more inclusive of phenotypes with some missing data, we performed an additional analysis using all phenotypes (n 5 31) and patients (n 5 44). Data were transformed into a Gower distance matrix and reduced to 2 dimensions by using tSNE before applying K-means clustering to partition the patients into three clusters. Fig E2, B , summarizes phenotypic characteristics of each cluster. Interestingly, cluster 2 was Fig 1, A and B , indicate SEMs for numerous WT transfections. Asterisks denote statistically significant reductions in GFP MFI versus WT (Fig 1, A) or WT1WT CARD11 (Fig 1, B) after stimulation, indicating DN activity (P < .05). C, Immunoblot for phospho-S6, total S6, and FLAG-CARD11 expression in Jurkat T cells transfected with CARD11 constructs with or without 20 minutes of stimulation with anti-CD3/CD28 antibodies. Data are representative of several independent experiments. D, Spot densitometric quantification of phospho-S6/ S6 ratio for each mutant normalized to WT (dashed line 5 1). Data are means 6 SDs for 2 to 3 experiments for each variant. E, Schematic diagram of CARD11 protein including new DN, LOF, hypermorphic, and benign (ie, no effect) variants. Stars indicate mutations with reduced phospho-S6 levels in Fig 1, D. characterized by lack of AD, skin bacterial infections, pneumonia, and allergic rhinitis but included patients with neutropenia and abnormal IgM and IgA levels. This cluster included all patients with R30G and R974C, most patients with R47H, and the single patient with R75Q mutations. Again, all phenotypic correlations predicted by these clusters are merely descriptive for this limited patient cohort.
The largest family analyzed included 10 patients from the United Kingdom (kindred 14) who presented with autosomal dominant inheritance of symptoms typically associated with dedicator of cytokinesis 8 deficiency, including increased serum IgE levels with significant atopic disease, recurrent respiratory tract infections, skin abscesses, and recurrent or persisting viral skin infections, such as molluscum contagiosum, herpes infections, or warts (Fig 3 and Table I ). Additionally, 2 patients had mycobacterial complications. Surprisingly, mild skeletal/ connective tissue abnormalities characteristic for the signal transducer and activator of transcription 3 DN autosomal dominant HIES were also observed in 6 of 10 affected family members. Patient III.4 died from disseminated mycosis fungoides. Immune phenotyping of patients' PBMCs from this family revealed low CD8 1 T-cell numbers and high CD4 1 T-cell numbers, with a shift toward the naive compartment and reduction of memory CD4
1 T cells. The B-cell compartment was normal.
Flow cytometric analyses of other patients, when available, often showed B-cell defects, including low total/memory B-cell counts in those with specific antibody deficiency and low IgM levels in several patients (Table III) . Other assays performed showed diminished mitogen-induced T-cell proliferation in the majority of patients tested and relatively normal frequencies of regulatory T cells, as previously reported (Table III) . Detailed clinical and laboratory findings for individual patients, where available, are included in Table E1 .
Primary cell signaling defects in CARD11 DN lymphocytes from patients
In 7 of the patients with confirmed DN mutations, primary cells were available for evaluation of NF-kB signaling by using short phorbol 12-myristate 13-acetate activation. Hallmarks of TCR-induced canonical NF-kB activation, including p65 phosphorylation and IkBa degradation, were impaired in all samples tested (Fig 4) . Impaired upregulation of activation markers at 24 hours and skewed cytokine secretion was also noted in multiple CD4
1 T-cell samples from patients, which is consistent with previous findings (see Figs E3 and E4 in this article's Online Repository at www.jacionline.org). Of note, NF-kB activation in lymphocytes from the patient with the V195L substitution, which was LOF but did not show DN activity in our transfection system, was also abnormal. Because haploinsufficiency does not likely lead to direct DN activity, 9 the result suggests either that other lesions explain the cellular and clinical phenotype or that the effects of this mutation on the pathway are not revealed by using our transfection system. The variability in phospho-S6 activation in the primary cell assay precludes making a definitive conclusion regarding its utility, although small but reproducible defects were observed in 4 patients tested from kindreds 6 and 19 ( Fig 5, A and B) . Moreover, we noted a more reproducible diminution of phospho-S6 could be observed in samples from patients with CARD11 DN mutations activated for 24 hours (Fig 5, C) .
DISCUSSION
In this report we describe multiple new DN CARD11 mutations associated with additional immunodeficient and dysregulatory conditions in human patients. Recent reports identified DN CARD11 mutations in a handful of patients presenting with severe AD and other allergic conditions with or without additional infections. 7, 9 The substantially larger cohort assembled here illuminates a broader phenotypic spectrum of disease tied to CARD11 DN mutations, including frequent sinopulmonary infections, cutaneous viral infections, neutropenia, hypogammaglobulinemia, and lymphoma (Table II) . Atopic disease was the cardinal feature noted in most patients (89%), frequently presenting in childhood as AD but also including asthma, allergic rhinitis, food allergies, and even eosinophilic esophagitis (Table II) . However, atopy was mild or absent in a number of patients examined in this report, with no measured differences in TCR-driven signaling responses. There were no obvious clinical similarities between nonatopic patients with CARD11 DN mutations beyond neutropenia (present in 4 patients). It is possible that atopic symptoms improved over time for some older adults for whom a detailed clinical history was lacking, similar to previously described patients. 9 Furthermore, unrelated patients with the same mutation (eg, R30Q and R72G) and even family members harboring identical mutations (eg, p.R47H and p.R187P) demonstrated differences in both the variety and severity of disease symptoms. From our characterization of this expanded patient cohort, we conclude that CARD11 DN mutations exhibit high penetrance and variable expressivity for several phenotypes that can extend beyond atopy. Other genetic variants or polymorphisms could certainly be influencing the heterogeneity and severity of phenotypes observed in certain patients.
Lack of atopic disease in patients with biallelic CARD11 null mutations, which are rarely associated with severe combined immune deficiency, is likely due to the relative lack of lymphocyte effector function. 32, 33 However, the absence of atopy observed in certain patients described here with CARD11 DN mutations, all of whom had lived into adulthood without major intervention, is surprising. Interestingly, unsupervised clustering analyses identified a subset of these patients from 4 kindreds that presented with neutropenia, abnormal immunoglobulin levels, and fewer skin/respiratory tract infections (Fig E2) , although the significance of these associations cannot be formally assessed within this limited cohort. We otherwise noted no Nonatopic phenotypes associated with bona fide DN mutations shed new light on important biological functions governed by CARD11 signaling in lymphocytes. For example, insufficient (eg, low IgM levels) or misdirected humoral responses appear to be a common outcome of attenuated CARD11 signaling with or without increased IgE levels. A number of families presented with more severe humoral defects resembling CVID, which might reflect both intrinsic defects in B-cell differentiation and/or poor T-cell help. Future studies aimed at elucidating specific abnormalities in class-switch recombination and plasma cell differentiation in patients' B cells would be helpful. The neutropenia noted in several patients was not associated with obvious bone marrow defects, which could suggest an autoimmune cause; indeed, CARD11 is primarily expressed in mature lymphocytes. However, given that this is a diagnosis of exclusion, further investigation is warranted. Cutaneous viral infections (eg, molluscum and herpes simplex virus 1) were also common to several patients. Impaired CD8 1 Tcell immunosurveillance could be a factor and might also help to explain tumor development in certain patients. Interestingly, patients with BENTA carrying GOF CARD11 mutations often present with molluscum and other viral infections (eg, EBV) and are at greater risk of lymphoma/leukemia development. 5 Unlike many patients with CARD11 DN mutations, T cells from patients with BENTA are only mildly ''anergic'' and proliferate relatively well in response to robust stimuli, even though IL-2 FIG 6 . Clinical diagnostic algorithm for recognizing patients with CARD11 DN mutations as a schematic diagram. Suspected patients typically present with atopy with or without cutaneous viral infections and respiratory tract infections. Simple laboratory diagnostic tests to pinpoint TCR-induced NF-kB activation defects in primary T cells from patients (eg, phospho-p65 and IkB degradation) are recommended before genomic sequencing analysis or after a CARD11 mutation is uncovered (eg, through WES). Within these selected patients, a mutation in the CARD domain (or N-terminal CC domain) is highly likely to be DN, whereas mutations in the rest of the protein are more likely benign. Functional testing (eg, Jurkat transfection assays for NF-kB activation) is recommended for all novel CARD11 variants, especially for those outside the CARD domain.
production is often reduced. 6, 34 There is also no evidence of T H 2 skewing or atopy in patients with BENTA described to date, although this has not been investigated thoroughly. Further studies are needed to elucidate how dysregulated CARD11 variant signaling leads to abnormal CD4 1 and CD8 1 T-cell responses that might predict expressivity of associated phenotypes (eg, atopy and viral skin infections). Based on our work and the work of others, we suspect alterations in TCR signal strength, metabolic reprogramming, and actin-dependent adhesion and motility could all be contributing factors. 13, [35] [36] [37] [38] Our workup of 48 new patients encompassing 25 novel/rare variants further clarifies whether mutations in specific regions of CARD11 are more or less likely to be pathogenic (Fig 6) . Notably, missense mutations in the N-terminal CARD domain (amino acids 1-110) are most likely to disrupt NF-kB (and, less reliably, mTORC1) signaling, probably by compromising interactions with BCL10 (and, by association, MALT1). The N-terminal CC domain (amino acids 130-200) is also a hotspot for pathogenic mutations, although it is still difficult to predict which variants in the CC domain will be LOF or DN; GOF mutations have been identified in the CARD, LATCH, and CC domains. 28, 39 In contrast, we have not found DN mutations residing between residues approximately 200 to 970, encompassing the C-terminal portion of the CC domain, the flexible linker, and the PDZ and SH3 domains. In fact, 2 mutations within this region (p.P495S and p.R848C) significantly boosted TCR-induced NF-kB activity in Jurkat cells; however, more work is required to determine whether and how this effect contributes to autoimmune manifestations in these patients. Unlike CARD/CC-associated GOF mutations found in patients with BENTA, these mutations did not drive constitutive NF-kB activation in the absence of antigen receptor stimulation. The linker itself (amino acids 449-667) contains an array of redundant repressive and activating elements that govern the complex intramolecular regulation of CARD11, 40, 41 making it unlikely to find single point mutations in the linker that affect CARD11 signaling. Finally, one new (p.R974C) and one previously confirmed DN mutation (p.R975W) were located in the guanylate kinase (GUK) domain), although nearby variants in this region showed no effect on TCRinduced NF-kB (p.V983M, p.E1028K, and p.D1152N).
In the end, LOF and/or DN activity was not detected in all rare variants from patients referred for a variety of phenotypes, including severe atopy. These results highlight the utility of our simple cell transfection assay in addition to the workup of primary patient cells whenever possible; indeed, as highlighted by the patient with the p.V195L mutation, the observed NF-kB signaling defect detected in primary cells cannot always be ascribed to DN activity. Although defects in mTORC1 signaling are also important, even small perturbations in cell culture conditions make quantification of differences in S6 phosphorylation extremely challenging for both Jurkat and primary T cells. Therefore we cannot currently recommend phospho-S6 quantification after short-term stimulation as a diagnostic assay for CARD11 DN mutations. Our comprehensive allelic series suggests that for CARD11, protein domain architecture might predict functional consequences of specific mutations. However, this too will require broader and more detailed structure-function analyses of the CARD11 protein before predictions could be used for clinical diagnoses.
For clinicians, this study also provides an improved differential diagnosis for immune deficiency and dysregulation linked to CARD11 mutations. An algorithm detailing our strategy for identifying and diagnosing these patients is depicted in Fig 6. Therefore heterozygous CARD11 DN mutations might be suspected and sought, either through analysis of existing exomes or included in other gene sequencing panels, in patients with histories of atopy (especially AD), often in combination with sinopulmonary bacterial infections or cutaneous viral infections (Fig 6) , especially when a dominant family history of any of those phenotypes is present. Failure to thrive, neutropenia, autoimmunity (eg, alopecia), specific antibody deficiency and/or CVID, and even lymphoma can also be noted. Even in patients without atopy but with a family history of dominant inheritance of any of the other phenotypes above, it might be worth testing for a heterozygous CARD11 DN mutation. A simple laboratory diagnostic test aimed at uncovering a TCR-induced NF-kB signaling defect in primary T cells is strongly recommended, even before sequencing is performed. Although identification of such mutations might not alter patient care currently, continued evaluation and reporting of new CARD11 variants (perhaps through a registry) will advance our understanding of specific phenotypic associations and hopefully inform future clinical management. Certainly, those with any such phenotypes in whom a rare heterozygous CARD11 mutation is found even by chance should lead to strong suspicion that it is causal, especially if it resides in the CARD domain. Nevertheless, functional tests, such as those described here, are imperative for definitive diagnosis.
